Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. Experiences with angiogenesis inhibitors in clinical trials indicate that short-term toxicities are mostly manageable. However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities. In addition, understanding the molecular mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967–974 (2005).
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Oncol. 3, 24–40 (2006).
Saltz, L. B. et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symp. abstract 238 (2007).
Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16–24 (2006).
Motzer, R. J. et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Ratain, M. J. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505–2512 (2006).
Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338 (2006).
Kim, D. W. et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 91, 4070–4076 (2006).
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N. K. & Cherrington, J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor b in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2, 471–478 (2003).
Carlomagno, F. et al. BAY 43–9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98, 326–334 (2006).
Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5, 835–844 (2006).
Augustin, H. G., Kozian, D. H. & Johnson, R. C. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 16, 901–906 (1994).
Denekamp, J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol. Oncol. 23, 217–225 (1984).
Folkman, J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643–651 (2003).
Dekker, R. J. et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 107, 4354–4363 (2006).
Folkman, J. & Kalluri, R. Cancer without disease. Nature 427, 787 (2004).
Verheul, H. M. & Pinedo, H. M. Inhibition of angiogenesis in cancer patients. Expert Opin. Emerg. Drugs 10, 403–412 (2005).
Bellamy, W. T. et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97, 1427–1434 (2001).
Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150–4166 (1998).
Kuenen, B. C. et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 22, 1500–1505 (2002).
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Wilhelm, S. M. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
Gasparini, G., Longo, R., Fanelli, M. & Teicher, B. A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol. 23, 1295–1311 (2005).
Kuenen, B. C. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657–1667 (2002).
Mross, K. et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer 43, 55–63 (2007).
Jubb, A. M., Oates, A. J., Holden, S. & Koeppen, H. Predicting benefit from anti-angiogenic agents in malignancy. Nature Rev. Cancer 6, 626–635 (2006).
Cobleigh, M. A. et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117–124 (2003).
Gordon, M. S. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).
Margolin, K. et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19, 851–856 (2001).
Faivre, S. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25–35 (2006).
Fiedler, W. et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105, 986–993 (2005).
O'Farrell, A. M. et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9, 5465–5476 (2003).
Awada, A. et al. Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855–1861 (2005).
Baker, S. D. et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J. Natl Cancer Inst. 94, 1883–1888 (2002).
Karp, J. E. et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-b-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 10, 3577–3585 (2004).
Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524 (2006).
Hurwitz, H. I., Honeycutt, W., Haley, S. & Favaro, J. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin. Colorectal Cancer 6, 66–69 (2006).
Ronnen, E. A., Kondagunta, G. V., Ginsberg, M. S., Russo, P. & Motzer, R. J. Long-term response with sunitinib for metastatic renal cell carcinoma. Urology 68, 672 e19–e20 (2006).
Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005).
Broxterman, H. J., Lankelma, J. & Hoekman, K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Updat. 6, 111–127 (2003).
Drevs, J. et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann. Oncol. 16, 558–565 (2005).
Robert, C., Faivre, S., Raymond, E., Armand, J. P. & Escudier, B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann. Intern. Med. 143, 313–314 (2005).
Herbst, R. S. & Sandler, A. B. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9 (Suppl. 1), 19–26 (2004).
Kabbinavar, F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).
Motzer, R. J., Hoosen, S., Bello, C. L. & Christensen, J. G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 15, 553–561 (2006).
Scappaticci, F. A. et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91, 173–180 (2005).
McCarty, M. E. & Ellis, L. M. Mechanisms of anti-angiogenic tyrosine kinase inhibition on wound healing — the obvious and not so obvious. Cancer Biol. Ther. 1, 127–129 (2002).
Duan, W. R., Patyna, S., Kuhlmann, M. A., Li, S. & Blomme, E. A. A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. J. Invest. Surg. 19, 245–254 (2006).
Haroon, Z. A. et al. SU5416 delays wound healing through inhibition of TGF-β 1 activation. Cancer Biol. Ther. 1, 121–126 (2002).
Ma, L. et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl Acad. Sci. USA 98, 6470–6475 (2001).
Sugrue, M. M. et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: Results from the BRiTE registry. Gastrointestinal Cancers Symp. abstract 345 (2007).
Wright, J. D. et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107, 83–89 (2006).
Lordick, F., Geinitz, H., Theisen, J., Sendler, A. & Sarbia, M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int. J. Radiat. Oncol. Biol. Phys. 64, 1295–1298 (2006).
Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581–611 (2004).
Verheul, H. M. et al. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3, 2187–2190 (1997).
Banks, R. E. et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 77, 956–964 (1998).
Weltermann, A. et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler. Thromb. Vasc. Biol. 19, 1757–1760 (1999).
Verheul, H. M. et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96, 4216–4221 (2000).
Rhee, J. S. et al. The functional role of blood platelet components in angiogenesis. Thromb. Haemost. 92, 394–402 (2004).
Kisucka, J. et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl Acad. Sci. USA 103, 855–860 (2006).
Selheim, F., Holmsen, H. & Vassbotn, F. S. Identification of functional VEGF receptors on human platelets. FEBS Lett. 512, 107–110 (2002).
Okuda, Y. et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci. 63, 477–484 (1998).
Reinmuth, N. et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15, 1239–1241 (2001).
te Velde, E. A., Kusters, B., Maass, C., de Waal, R. & Borel Rinkes, I. H. Histological analysis of defective colonic healing as a result of angiostatin treatment. Exp. Mol. Pathol. 75, 119–123 (2003).
Nash, G. F., Walsh, D. C. & Kakkar, A. K. The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2, 608–613 (2001).
Zucker, S. et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int. J. Cancer 75, 780–786 (1998).
Koomagi, R. & Volm, M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int. J. Cancer 79, 19–22 (1998).
Shoji, M. et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am. J. Pathol. 152, 399–411 (1998).
Pawlinski, R., Pedersen, B., Erlich, J. & Mackman, N. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb. Haemost. 92, 444–450 (2004).
Ma, L. et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 65, 5365–5373 (2005).
Rickles, F. R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb. 35, 103–110 (2006).
Heymach, J. V. et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 10, 5732–5740 (2004).
Pearson, J. D. Normal endothelial cell function. Lupus 9, 183–188 (2000).
Cines, D. B. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91, 3527–3561 (1998).
Taraseviciene-Stewart, L. et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427–438 (2001).
Bombeli, T., Karsan, A., Tait, J. F. & Harlan, J. M. Apoptotic vascular endothelial cells become procoagulant. Blood 89, 2429–2442 (1997).
Hathcock, J. J. Flow effects on coagulation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 26, 1729–1737 (2006).
Bergmeier, W. et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc. Natl Acad. Sci. USA 103, 16900–16905 (2006).
Kilickap, S., Abali, H. & Celik, I. Bevacizumab, bleeding, thrombosis, and warfarin. J. Clin. Oncol. 21, 3542 (2003).
Meyer, T. et al. Targeting angiogenesis in cancer: bevacizumab-induced platelet activation as a possible cause for unexpected arterial thromboembolic events in clinical trials. ASH annual meeting, abstract 1091 (2006).
Hong, C. C., Peterson, Q. P., Hong, J. Y. & Peterson, R. T. Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. Curr. Biol. 16, 1366–1372 (2006).
Veronese, M. L. et al. Mechanisms of hypertension associated with BAY 43–9006. J. Clin. Oncol. 24, 1363–1369 (2006).
Sane, D. C., Anton, L. & Brosnihan, K. B. Angiogenic growth factors and hypertension. Angiogenesis 7, 193–201 (2004).
Sica, D. A. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. 24, 1329–1331 (2006).
Miller, K. D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792–799 (2005).
Hariawala, M. D. et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J. Surg. Res. 63, 77–82 (1996).
Li, B. et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39, 1095–1100 (2002).
Eppler, S. M. et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20–32 (2002).
Scotland, R. S. et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 111, 796–803 (2005).
Gelinas, D. S., Bernatchez, P. N., Rollin, S., Bazan, N. G. & Sirois, M. G. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. 137, 1021–1030 (2002).
Umemoto, S. et al. Different effects of amlodipine and enalapril on the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase pathway for induction of vascular smooth muscle cell differentiation in vivo. Hypertens Res. 29, 179–186 (2006).
Yang, R. et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 39, 815–820 (2002).
Ciuffetti, G. et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J. Hypertens. 21, 2297–2303 (2003).
Matsuura, A. et al. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem. Biophys. Res. Commun. 235, 713–716 (1997).
Williams, G. H. in Harrisons principles of internal medicine 246 (McGraw–Hill, USA, 2004).
Yau, T. M. et al. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 112, I123–I128 (2005).
Tam, C. S. et al. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am. J. Hematol. 77, 72–76 (2004).
Ozcan, C., Wong, S. J. & Hari, P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980–982 (2006).
Glusker, P., Recht, L. & Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980–982 (2006).
Govindarajan, R., Adusumilli, J., Baxter, D. L., El-Khoueiry, A. & Harik, S. I. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J. Clin. Oncol. 24, e48 (2006).
Desai, J. et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal tumors. Ann. Int. Med. 145, 660–664 (2006).
Gerard, A. C. et al. Structural changes in the angiofollicular units between active and hypofunctioning follicles align with differences in the epithelial expression of newly discovered proteins involved in iodine transport and organification. J. Clin. Endocrinol. Metab. 87, 1291–1299 (2002).
Wang, J. F. et al. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J. Endocrinol. 157, 5–12 (1998).
Willett, C. G. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23, 8136–8139 (2005).
Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004).
Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560–H576 (2006).
de Vriese, A. S. et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12, 993–1000 (2001).
Sugimoto, H. et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278, 12605–12608 (2003).
Hara, A. et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 69, 1986–1995 (2006).
Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
Eremina, V. et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol. 17, 724–735 (2006).
Yang, C. C., Chu, K. C. & Yeh, W. M. Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J. Clin. Lab. Anal. 17, 85–89 (2003).
Jacobsen, J. et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 93, 297–302 (2004).
Masuda, Y. et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am. J. Pathol. 159, 599–608 (2001).
Guan, F., Villegas, G., Teichman, J., Mundel, P. & Tufro, A. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am. J. Physiol. Renal Physiol. 291, F422–F428 (2006).
Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A. & Satow, Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55, 5687–5692 (1995).
Peichev, M. et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 95, 952–958 (2000).
Bellamy, W. T. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin. Oncol. 28, 551–559 (2001).
Mohle, R., Green, D., Moore, M. A., Nachman, R. L. & Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl Acad. Sci. USA 94, 663–668 (1997).
Ohm, J. E. & Carbone, D. P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23, 263–272 (2001).
Robert, C. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 6, 491–500 (2005).
Strumberg, D. et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur. J. Cancer 42, 548–556 (2006).
Tsao, A. S., Kantarjian, H., Cortes, J., O'Brien, S. & Talpaz, M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 98, 2483–2487 (2003).
Gimbrone, M. A., Jr. et al. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 222, 33–36 (1969).
Hanson, S. R. & Slichter, S. J. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 66, 1105–1109 (1985).
Slichter, S. J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus. Med. Rev. 18, 153–167 (2004).
Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391–400 (2004).
Podar, K. et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA 103, 19478–19483 (2006).
Goodlad, R. A. et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 27, 2133–2139 (2006).
Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–2189 (2000).
Huang, J. et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl Acad. Sci. USA 100, 7785–7790 (2003).
McCarty, M. F. et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol. Cancer Ther. 3, 1041–1048 (2004).
Polverino, A. et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66, 8715–8721 (2006).
Baffert, F. et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 290, H547–H559 (2006).
H.V. is a recipient of the American Society of Clinical Oncology (ASCO) Young Investigator's award 2006 and of a Drug Development fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institution. This work was supported in part by The Adriana van Coevorden Society (H.V.) and for a major part by the Spinoza award (H.M.P.).
The authors declare no competing financial interests.
- Acral erythema
Redness of the most distal extremities caused by capillary congestion (a general sign of inflammation).
Located in the carotid arteries in the neck, these receptors are stretched by high blood pressure, reducing the activation of the vasomotor centre. They also activate the vasomotor centre in response to low blood pressure.
- Dendritic cells
Immune cells that process antigens and present them to other immune cells.
Alteration in brain function and/or structure. Common symptoms include progressive loss of memory and cognitive ability, subtle personality changes, inability to concentrate, lethargy and progressive loss of consciousness.
- Gastrointestinal perforations
Can occur in the wall of the stomach, small intestine or large bowel, resulting in intestinal contents flowing into the abdominal cavity.
A capillary bed surrounded by the Bowman's capsule in the kidney, which regulates blood filtration and urine generation.
An inadequate blood supply to an organ.
- Left ventricular ejection fraction
The fraction of blood pumped out of the left ventricle with each heart beat.
- Leukopenia and lymphopenia
A low leukocyte or lymphocyte count in the circulating blood, both of which increase the risk of infections.
The precursor cells of platelets, located in the bone marrow.
- Perivascular cells
Cells that surround vessels, including pericytes, myofibroblasts and smooth muscle cells.
Cells that form the visceral epithelium in the kidney and are involved in the glomerular filtration barrier.
- Reversible posterior leukoencephalopathy syndrome
A rapidly evolving neurological syndrome. The underlying mechanism seems to be related to an increased permeability and reactivity of brain vasculature.
- Subungual splinter bleeding
A small amount of bleeding that occurs under a finger or toe nail.
A low platelet count in the circulating blood.
- Vascular resistance
The resistance to flow that must be overcome to push blood though a vessel; determined by diameter, stiffness and length of the vessel.
About this article
Cite this article
Verheul, H., Pinedo, H. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7, 475–485 (2007). https://doi.org/10.1038/nrc2152
Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin
Inflammatory Bowel Diseases (2021)
Surface Modification with NGF-Loaded Chitosan/Heparin Nanoparticles for Improving Biocompatibility of Cardiovascular Stent
Stem Cells International (2021)
Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms
JAMA Oncology (2021)